Axio BioPharma
Axio BioPharma builds a vendor-neutral data network for biopharma, combining a high-throughput monoclonal antibody lab (Forge) in Madison, WI with an in-development federated intelligence platform (Lattice), serving biotech sponsors and CDMOs.
- Company typePrivate
- Founded2024
- HeadquartersMadison, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Axio BioPharma does
Axio BioPharma is a Seed-stage biotechnology company founded in 2024 in Madison, Wisconsin, building a vendor-neutral data network for biopharma. The company operates a platform-plus-modules architecture: Axio Forge is a US-based high-throughput biologics laboratory producing approximately 100 monoclonal antibodies per week with 3-5 week turnaround using CHO and HEK293 expression systems, running on a fee-for-service revenue model. Axio Lattice is a federated intelligence platform in development, comprising four components — Node (local system connections), Rosetta (standardization layer), Blueprints (pre-built workflows), and Signal (pattern surfacing) — designed to connect manufacturing process data across sponsor and CDMO sites without centralizing it, enabling cross-site tech transfer, batch decisions, and investigations via a planned recurring subscription model. The company's BAMI (Biomanufacturing AI Maturity Index) is a six-level assessment framework across five dimensions that functions as thought-leadership content marketing and a top-of-funnel for Lattice adoption.
The company's go-to-market is enterprise field sales targeting two primary customer segments: biotech companies developing biologic therapeutics (seeking faster process understanding and tech transfer) and contract development and manufacturing organizations (seeking to standardize knowledge and scale intelligence across sites). Distribution is single-country/domestic through direct engagement led by Chief Commercial Officer Dave Watrous. The company was founded by Justin Byers (CEO) and Brian Staats (CTO, 20+ years bioinformatics) and has assembled an advisory board including former Catalent VP R&D Greg Bleck, biologics veteran Graham Brearley, Samsung Biologics/Jubilant alumnus Patrick Haffey, and Jim Wilson (ZEA Biosciences CEO, Shepherd Ventures III). Axio was named a Round 1 awardee of the Innovation to Commercialization Pipeline program led by Forward BIOLABS and BioForward Wisconsin in February 2026.
Axio's core competitive thesis is structural neutrality — large CDMOs cannot credibly host a cross-sponsor data network and sponsors will not place proprietary process data on a competitor's platform, so an independent vendor is positioned as the only viable coordinator. The wet-lab Forge engine generates real manufacturing data that seeds the Lattice network, and each deployment compounds reusable schemas and connectors. The company is privately held at Seed stage with approximately $1.4M in disclosed funding; no revenue figures or named customer logos have been disclosed.
Axio BioPharma firmographics
Firmographics- Name
- Axio BioPharma
- Legal name
- Axio BioPharma Inc.
- Website
- https://axiobiopharma.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Axio BioPharma builds a vendor-neutral data network for biopharma, combining a high-throughput monoclonal antibody lab (Forge) in Madison, WI with an in-development federated intelligence platform (Lattice), serving biotech sponsors and CDMOs.
- Ownership category
- akta.pro rank
Axio BioPharma industry classification
Industry- Product category
- Biologics Manufacturing Software & Data Infrastructure
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI) (HDAEANAI), Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Axio BioPharma is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Axio BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Axio Forge - Fee-for-Service Lab: Non-GMP antibody lab providing fee-for-service revenue. High-throughput antibody lab generating fee-for-service revenue. Zero incremental capex for current growth. Generates real manufacturing data that seeds the Lattice network.
- Axio Lattice - Subscription Platform: Federated data platform with recurring subscription revenue. Vendor-neutral infrastructure connecting manufacturing data across sponsors and CDMOs. Data stays local; meaning is standardized. High-margin recurring revenue model.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Fee-for-service laboratory execution |
| Subscription | Monthly | Federated data platform subscription |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Axio BioPharma product offering
Product offeringCore offering
Axio BioPharma provides AI-ready biologics manufacturing through two integrated offerings: Axio Forge, a US-based high-throughput laboratory producing approximately 100 monoclonal antibodies per week with 3–5 week turnaround using CHO and HEK293 expression systems on a fee-for-service basis; and Axio Lattice, a federated intelligence data platform (in development) that connects and standardizes manufacturing process data across sponsor and CDMO sites without replacing existing systems or centralizing raw data. The offerings are supported by the BAMI (Biomanufacturing AI Maturity Index), a six-level framework and self-assessment tool that evaluates AI readiness across five dimensions.
Product overview
Axio BioPharma offers a platform-plus-modules architecture centered on AI-ready biologics manufacturing. The core offerings are Axio Forge (a US-based high-throughput antibody lab providing fee-for-service mAb production) and Axio Lattice (a federated data intelligence platform under development that connects manufacturing data across sponsors and CDMOs without centralizing it). The BAMI (Biomanufacturing AI Maturity Index) assessment framework complements the platform by helping organizations evaluate their AI readiness across five dimensions. Forge generates real execution data that informs Lattice development, while Lattice is designed to enable cross-site process intelligence, investigations, and decision-making.
Differentiator
Problem solved
Functional benefit
Brands
- Forge: High-throughput monoclonal antibody (mAb) production lab in Madison, WI offering ~100 antibodies/week with 3-5 week turnaround using CHO and HEK293 expression systems.
- Lattice
- BAMI
Products and services
- Axio Forge US-based high-throughput biologics laboratory in Madison, Wisconsin providing fee-for-service monoclonal antibody production. Produces approximately 100 antibodies per week with a 3–5 week turnaround, supporting CHO and HEK293 transient expression systems, Protein A purification, and standard analytics (purity, aggregation, yield). End-to-end workflow from sequence or plasmid to purified antibody with direct bench-scale scientist access and automated DOE.
- Axio Lattice Federated intelligence data platform (in development) connecting process data across sites, systems, and partners without replacing existing technology stacks or centralizing raw data. Comprises Node (connects to local systems), Rosetta (standardizes structure and terminology), Blueprints (pre-built workflows), and Signal (surfaces patterns and decision support). Supports tech transfer, batch decisions, cross-site comparability, and investigations across sponsors and CDMOs on a recurring subscription model.
Companies that use Axio BioPharma
Customer profileSegments2 records
Ideal customer profiles2 records
Axio BioPharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
Axio BioPharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Forward BIOLABScoreForward BIOLABS leads the Innovation to Commercialization Pipeline (ICP) program in partnership with BioForward Wisconsin. Axio BioPharma was selected as a Round 1 awardee of the ICP program, which supports early-stage biohealth companies across Wisconsin with targeted resources to reduce commercialization risk, accelerate growth, and strengthen investment readiness.
- BioForward WisconsincoreBioForward Wisconsin is the unified voice of Wisconsin's biohealth industry and lead organization for the Wisconsin Biohealth Tech Hub. Partners with Forward BIOLABS on the ICP program to support early-stage biohealth companies including Axio BioPharma.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Axio BioPharma competitors and assessment
Company assessmentDirect peers
- TetraScience: Provides a federated, vendor-neutral scientific data cloud for life sciences R&D and manufacturing, with AI-ready data lake architecture. Highly comparable to Axio Lattice in approach (data stays local, meaning is standardized) and target customers (biopharma sponsors and CDMOs).
- Benchling: Cloud-based informatics platform for biotech R&D, including biologics development. Comparable in serving modern, AI-forward biologics teams with structured data capture, though focused upstream of manufacturing where Axio Lattice targets cross-site process intelligence.
- Sapio Sciences: LIMS/ELN platform with growing AI and lab automation capabilities, serving biopharma and CDMOs. Comparable as an informatics vendor modernizing lab and process data capture for biologics workflows.
- Genedata: Enterprise biopharma R&D and bioprocess informatics platform used across large biologics sponsors. Comparable as a deep bioprocess data platform targeting similar sponsor customers with structured process data.
- Dotmatics: Scientific R&D informatics platform (LIMS, ELN, data management) used across biopharma. Comparable as a vendor offering structured data infrastructure that biopharma teams can extend into manufacturing workflows.
- IDBS: Biopharma data management and process informatics platform with strong bioprocess heritage. Comparable as an established informatics vendor serving biopharma R&D and manufacturing data needs.
Emerging players
- Aizon: AI platform purpose-built for biopharma manufacturing with GMP data cloud and analytics. Comparable as a focused biomanufacturing AI vendor but more narrowly applied to batch analytics rather than cross-site federated coordination.
- Apprentice.io: Manufacturing intelligence and execution platform for life sciences, including CDMOs. Comparable as an emerging vendor bringing modern software and AI to biomanufacturing workflows, though focused on shop-floor execution rather than cross-organizational data federation.
Broad incumbents
- Veeva Systems: Dominant life sciences cloud platform with Vault-based manufacturing, quality, and clinical solutions deeply embedded in pharma sponsors and CDMOs. Comparable as an incumbent data platform, though not vendor-neutral across sponsor/CDMO boundaries — exactly the gap Axio targets.
- Dassault Systèmes BIOVIA: Scientific informatics suite covering lab, formulation, and bioprocess workflows for large biopharma. Comparable as an incumbent serving biomanufacturing data needs with deep installed base, though typically deployed within single organizations rather than across sponsor/CDMO networks.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Axio BioPharma social profiles
Digital presenceAxio BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Axio BioPharma leadership team
Management profileNumber of profiles
Profiles7 records
Axio BioPharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Axio BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Axio BioPharma
What does Axio BioPharma do?
Axio BioPharma provides AI-ready biologics manufacturing through two integrated offerings: Axio Forge, a US-based high-throughput laboratory producing approximately 100 monoclonal antibodies per week with 3–5 week turnaround using CHO and HEK293 expression systems on a fee-for-service basis; and Axio Lattice, a federated intelligence data platform (in development) that connects and standardizes manufacturing process data across sponsor and CDMO sites without replacing existing systems or centralizing raw data. The offerings are supported by the BAMI (Biomanufacturing AI Maturity Index), a six-level framework and self-assessment tool that evaluates AI readiness across five dimensions.
Is Axio BioPharma a public or private company?
Axio BioPharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Axio BioPharma founded?
Axio BioPharma was founded in 2024. It employs 11 to 50 people.
Where is Axio BioPharma based?
Axio BioPharma is headquartered in Madison, United States, in the North America region.
How does Axio BioPharma make money?
Two revenue lines are on record. Axio Forge - Fee-for-Service Lab is the primary driver. The others are axio Lattice - Subscription Platform.
Who are Axio BioPharma's main competitors?
Direct peers on record are TetraScience, Benchling, Sapio Sciences, Genedata, Dotmatics and IDBS. Emerging players are Aizon and Apprentice.io. Broad incumbents are Veeva Systems and Dassault Systèmes BIOVIA.
Does Axio BioPharma have an API?
No public API is recorded for Axio BioPharma.
What industry is Axio BioPharma in?
Axio BioPharma's product category is Biologics Manufacturing Software & Data Infrastructure. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAEANAI, AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI). Its NAICS code is 541714 and its SIC code is 8731.